UK markets closed

Guerbet SA (0ELV.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
32.84-0.71 (-2.11%)
At close: 05:45PM GMT

Guerbet SA

15, rue des Vanesses
Zone Paris Nord II
Villepinte 93420
France
33 1 45 91 50 00
https://www.guerbet.com

Sector(s)
Industry
Full-time employees2,839

Key executives

NameTitlePayExercisedYear born
Mr. David HaleCEO, MD & GM816.43kN/A1968
Mr. Philippe BourrinetChief Pharmacist, Deputy CEO, Senior VP of Development, Medical & Regulatory Affairs and Deputy MD11.5kN/A1968
Mr. Jerome EstampesCFO and Senior VP of Business Development & LicensingN/AN/AN/A
Ms. Sarah DayreSenior VP of Technical Operations & Interim Chief PharmacistN/AN/AN/A
Ms. Charlotte BamiereDirector of Legal AffairsN/AN/AN/A
Ms. Petra ZalabakSenior Vice President of Human Resources & Corporate Social ResponsibilityN/AN/AN/A
Mr. Jean-Francois BlancSenior Vice President of Interventional ImagingN/AN/AN/A
Mr. Francois NicolasSenior VP of R&D, R&I and Chief Digital OfficerN/AN/A1971
Ms. Valérie BrissartSenior Vice President of Diagnostic ImagingN/AN/AN/A
Mr. Mathieu ElieSenior Vice President of Commercial Operations - Asia-PacificN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. The company was incorporated in 1926 and is headquartered in Villepinte, France.

Corporate governance

Guerbet SA’s ISS governance QualityScore as of 1 March 2024 is 8. The pillar scores are Audit: 6; Board: 6; Shareholder rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.